[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

GB201615914D0 - Pharmaceutical composition - Google Patents

Pharmaceutical composition

Info

Publication number
GB201615914D0
GB201615914D0 GBGB1615914.7A GB201615914A GB201615914D0 GB 201615914 D0 GB201615914 D0 GB 201615914D0 GB 201615914 A GB201615914 A GB 201615914A GB 201615914 D0 GB201615914 D0 GB 201615914D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical composition
pharmaceutical
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB1615914.7A
Other versions
GB2554091A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mexichem Fluor SA de CV
Original Assignee
Mexichem Fluor SA de CV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mexichem Fluor SA de CV filed Critical Mexichem Fluor SA de CV
Priority to GB1615914.7A priority Critical patent/GB2554091A/en
Publication of GB201615914D0 publication Critical patent/GB201615914D0/en
Priority to CA3037107A priority patent/CA3037107C/en
Priority to EP17777637.4A priority patent/EP3515425B1/en
Priority to BR112019005168A priority patent/BR112019005168A2/en
Priority to AU2017328910A priority patent/AU2017328910B2/en
Priority to MX2019003099A priority patent/MX2019003099A/en
Priority to US16/334,144 priority patent/US10792256B2/en
Priority to CN201780057318.5A priority patent/CN109715148A/en
Priority to JP2019515225A priority patent/JP6781828B2/en
Priority to PCT/GB2017/052764 priority patent/WO2018051133A1/en
Priority to ES17777637T priority patent/ES2877575T3/en
Publication of GB2554091A publication Critical patent/GB2554091A/en
Priority to ZA2019/02051A priority patent/ZA201902051B/en
Priority to US16/882,979 priority patent/US11311502B2/en
Priority to US16/883,016 priority patent/US11077076B2/en
Priority to US17/694,972 priority patent/US11883372B2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB1615914.7A 2016-09-19 2016-09-19 Pharmaceutical composition Withdrawn GB2554091A (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
GB1615914.7A GB2554091A (en) 2016-09-19 2016-09-19 Pharmaceutical composition
ES17777637T ES2877575T3 (en) 2016-09-19 2017-09-18 Pharmaceutical composition comprising salmeterol
US16/334,144 US10792256B2 (en) 2016-09-19 2017-09-18 Pharmaceutical composition
JP2019515225A JP6781828B2 (en) 2016-09-19 2017-09-18 Pharmaceutical composition
BR112019005168A BR112019005168A2 (en) 2016-09-19 2017-09-18 pharmaceutical composition, sealed container, metered dose inhaler, and methods for treating a patient suffering or likely to suffer from a respiratory disorder, for improving the stability of a pharmaceutical composition and the aerosolization performance of a pharmaceutical composition global warming potential of a pharmaceutical composition
AU2017328910A AU2017328910B2 (en) 2016-09-19 2017-09-18 Pharmaceutical composition
MX2019003099A MX2019003099A (en) 2016-09-19 2017-09-18 Pharmaceutical composition.
CA3037107A CA3037107C (en) 2016-09-19 2017-09-18 Stable pharmaceutical compositions comprising salmeterol and 1,1-difluoroethane (hfa-152a) suitable for use in metered dose inhalers (mdis)
CN201780057318.5A CN109715148A (en) 2016-09-19 2017-09-18 Pharmaceutical composition
EP17777637.4A EP3515425B1 (en) 2016-09-19 2017-09-18 Pharmaceutical composition comprising salmeterol
PCT/GB2017/052764 WO2018051133A1 (en) 2016-09-19 2017-09-18 Pharmaceutical composition
ZA2019/02051A ZA201902051B (en) 2016-09-19 2019-04-02 Pharmaceutical composition
US16/882,979 US11311502B2 (en) 2016-09-19 2020-05-26 Pharmaceutical composition
US16/883,016 US11077076B2 (en) 2016-09-19 2020-05-26 Pharmaceutical composition
US17/694,972 US11883372B2 (en) 2016-09-19 2022-03-15 Pharmaceutical composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1615914.7A GB2554091A (en) 2016-09-19 2016-09-19 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
GB201615914D0 true GB201615914D0 (en) 2016-11-02
GB2554091A GB2554091A (en) 2018-03-28

Family

ID=57288758

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1615914.7A Withdrawn GB2554091A (en) 2016-09-19 2016-09-19 Pharmaceutical composition

Country Status (1)

Country Link
GB (1) GB2554091A (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2573297A (en) * 2018-04-30 2019-11-06 Mexichem Fluor Sa De Cv Pharmaceutical composition
WO2021151857A1 (en) * 2020-01-28 2021-08-05 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation
WO2024201526A1 (en) * 2023-03-28 2024-10-03 Cipla Limited Pharmaceutical composition of ensifentrine with pharmaceutically acceptable propellants

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2259915B1 (en) * 2005-03-15 2007-12-16 Laboratorio Aldo-Union, S.A. NEW STABLE FORMULATION OF AEROSOLS IN SUSPENSION AND PROCEDURE OF OBTAINING.
GB201108039D0 (en) * 2011-05-13 2011-06-29 Mexichem Amanco Holding Sa Compositions

Also Published As

Publication number Publication date
GB2554091A (en) 2018-03-28

Similar Documents

Publication Publication Date Title
IL265360B (en) Pharmaceutical composition
IL265260B (en) Pharmaceutical composition
IL271986A (en) Pharmaceutical composition
IL262654A (en) Pharmaceutical composition
IL265349A (en) Pharmaceutical composition
GB201712159D0 (en) Pharmaceutical composition
IL272419A (en) Pharmaceutical composition
PT3583943T (en) Pharmaceutical composition
GB201506526D0 (en) Medicinal composition
IL263040A (en) Pharmaceutical composition comprising eteplirsen
GB201521462D0 (en) Pharmaceutical composition
GB201719447D0 (en) Pharmaceutical composition
GB201615917D0 (en) Pharmaceutical composition
EP3727485C0 (en) Pharmaceutical composition
GB201515310D0 (en) Pharmaceutical composition
PL3454838T3 (en) Pharmaceutical composition
GB201615914D0 (en) Pharmaceutical composition
GB201520862D0 (en) Pharmaceutical composition
IL263999A (en) Pharmaceutical compositions
GB201615910D0 (en) Pharmaceutical composition
IL265436B (en) Pharmaceutical composition
ZA201705782B (en) Pharmaceutical compositions
PL3424500T3 (en) Pharmaceutical composition comprising famitinib
GB201620519D0 (en) Pharmaceutical composition
IL265428A (en) Pharmaceutical composition

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)